ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an ...
Acelyrin confirms unsolicited indication of interest from Concentra Biosciences
Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...
Acelyrin jumps 11% on acquisition offer from Concentra Biosciences
Acelyrin (NASDAQ:SLRN) received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The proposal includes a cash payment of $3.00 per share, along with a ...